Our Services
Medical Information
Helpful Resources
Published on: 3/18/2026
If your ulcerative colitis is not improving, clinical trial eligibility typically requires moderate to severe disease with objective signs of inflammation, steroid dependence or refractoriness, and prior failure of advanced therapies. Common exclusions include severe complications, active infections, recent cancers, and pregnancy.
Trials can provide access to emerging treatments with close monitoring, but also carry risks and possible placebo assignment. Key eligibility details—biomarkers, age ranges, washout periods, and readiness assessment—are explained below.
Not sure whether your symptoms point to worsening ulcerative colitis or something else? Before your next gastroenterologist visit, take a free, instant, online symptom check to clarify what may be driving your symptoms and help you navigate next steps with confidence.
Reviewed for medical accuracy: 07/03/2026
If you're living with ulcerative colitis (UC) and your symptoms aren't improving, you're not alone. Even with today's medications—including biologics and advanced small-molecule therapies—some people continue to experience flares, bleeding, urgency, and fatigue. When standard treatments aren't enough, clinical research studies may offer access to emerging therapies.
Understanding the eligibility criteria for UC clinical research can help you decide whether participating in a study is a realistic and appropriate next step.
Ulcerative colitis is a chronic inflammatory bowel disease that affects the lining of the colon. Treatment goals, according to major gastroenterology guidelines, include:
If your UC isn't improving despite appropriate treatment, it may be classified as:
In these cases, doctors may discuss switching medications—or potentially enrolling in a clinical trial.
UC clinical research studies test new medications, combinations of treatments, dosing strategies, or treatment approaches. These trials are conducted under strict regulatory and ethical oversight.
Clinical trials typically move through phases:
Many current studies focus on:
However, not everyone qualifies. That's where eligibility criteria for UC clinical research become important.
Eligibility criteria are specific medical and safety requirements that determine who can participate in a study. These criteria protect participants and ensure the research produces reliable results.
They are divided into:
These criteria are based on scientific evidence, regulatory standards, and safety data.
While each trial is different, many share similar core requirements.
Participants must have a confirmed UC diagnosis, usually established by:
Most trials focus on moderate to severe UC. This is typically measured using scoring systems such as:
You may need:
Many studies require:
Newer trials may specifically recruit:
The exact eligibility criteria for UC clinical research often depend on where the new therapy fits in the treatment pathway.
Most studies enroll adults aged:
Some newer research includes adolescent populations, but these are separate protocols.
Certain conditions may prevent participation due to safety concerns.
You may not qualify if you have:
Because many UC treatments suppress the immune system, trials often exclude patients with:
Washout periods are common. You may need to stop certain medications before enrolling.
Some trials exclude patients with recent or active malignancies, although stable, treated cancers may sometimes be allowed.
Most interventional drug trials exclude pregnant or breastfeeding individuals due to unknown risks.
Recent updates in the eligibility criteria for UC clinical research reflect a shift toward precision medicine and broader inclusion.
As more patients use advanced therapies, newer trials are increasingly designed for:
Some studies now use:
This helps identify patients more likely to respond to targeted treatments.
There is growing effort to:
More trials now specifically include people who cannot taper off steroids without flaring.
Participation may offer:
However, there are also risks:
Every study includes an informed consent process explaining risks and benefits in detail.
If your UC isn't improving, consider:
Before exploring trials, it may help to assess your current symptoms and document what you're experiencing. You can use Ubie's free AI-powered Ulcerative Colitis symptom checker to better understand your condition and prepare for your next appointment with detailed information to share with your doctor.
Clinical trials are carefully regulated, but they are still medical interventions. If you are experiencing:
Seek urgent medical care immediately. Some UC complications can become life-threatening.
Even if your symptoms are less severe but persistent, it's important to speak to a doctor. Ongoing inflammation can increase long-term risks, including hospitalization and colorectal cancer.
Bring these questions to your appointment:
Your gastroenterologist can help determine whether clinical research is appropriate—or whether adjusting your current treatment plan is a better next step.
If your ulcerative colitis isn't improving, you do have options. The eligibility criteria for UC clinical research are designed to protect participants and ensure meaningful results, but they also reflect evolving treatment needs.
You may qualify if you have:
Clinical research is not a last resort—but it is a serious decision that should be made in partnership with a qualified healthcare provider.
If your symptoms are persistent, worsening, or affecting your quality of life, do not ignore them. Speak to a doctor about your situation, especially if anything feels severe or potentially life-threatening. Early evaluation and informed decision-making can help you move toward better control and improved health.
(References)
* Feagan BG, Sandborn WJ, D'Haens G, et al. Clinical trials in inflammatory bowel disease: current challenges and future directions. Gut. 2020 Jan;69(1):16-24. doi: 10.1136/gutjnl-2019-319324. Epub 2019 Nov 22. PMID: 31753896.
* Varkey J, Afzali A. Defining treatment refractory ulcerative colitis: a systematic review. J Crohns Colitis. 2022 Mar 19;16(3):398-410. doi: 10.1093/ecco-jcc/jjab156. PMID: 34509163.
* Regueiro M, D'Haens G, Sandborn WJ. Ulcerative Colitis: Evolving Therapeutic Strategies and Clinical Trial Endpoints. Gastroenterology. 2020 Dec;159(6):2040-2051. doi: 10.1053/j.gastro.2020.08.067. PMID: 32905786.
* Colombel JF, Sandborn WJ, D'Haens G, et al. Patient Selection and Eligibility for Clinical Trials in Inflammatory Bowel Disease: An Evolving Landscape. J Crohns Colitis. 2023 Feb 1;17(2):348-360. doi: 10.1093/ecco-jcc/jjac181. PMID: 36477154.
* Sandborn WJ. Challenges and Progress in the Development of New Therapies for Ulcerative Colitis. Gastroenterology. 2020 Dec;159(6):2052-2067. doi: 10.1053/j.gastro.2020.08.068. PMID: 32905787.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.